Evidence map›Paper›PMID 32661403›Full record

ArticleNature ecology & evolution2020

Phylogenetic analyses with systematic taxon sampling show that mitochondria branch within Alphaproteobacteria.

Lu Fan, Dingfeng Wu, Vadim Goremykin, Jing Xiao, Yanbing Xu, Sriram Garg, Chuanlun Zhang, William F Martin, Ruixin Zhu

2 registry-linked trialsAbstract read
PubMed Publisher
In one paragraph

Article in Nature ecology & evolution, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 66 papers.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06927297 phase1recruitingnot on this mapstarted 2025, after this paper: background citation

A Clinical Trial to Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of an Engineered Mitochondrial Vaccine in Treatment of Advanced Solid Tumors

TypeinterventionalSponsorWest China HospitalRan2025 to 2028Enrolled12ConditionsAdvanced Solid Tumor Malignancies, Advanced Solid MalignanciesArmsEngineered mitochondrial vaccine
NCT07572864 phase2recruitingnot on this mapstarted 2026, after this paper: background citation

Efficacy and Safety of Immune Checkpoint Inhibitors in Combination With Engineered Mitochondrial Vaccine as Neoadjuvant and Adjuvant Therapy for Resectable Head and Neck Squamous Cell Carcinoma: A Single-Arm, Single-Center Clinical Study.

TypeinterventionalSponsorWest China HospitalRan2026 to 2028Enrolled9ConditionsHead and Neck Squamous Cell CarcinomaArmsEngineered Mitochondrial Vaccine (IMP3-Mito), Immune checkpoint inhibitor (ICI)
3 · Its place in the literature

Who cites it

66 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Toward a genomic understanding of the tree of life.Molecular biology and evolution · 2026
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Evolution of plant metabolism: the state-of-the-art.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2024
    Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Comparative Mitogenomics Analysis Revealed Evolutionary Divergence amongInternational journal of molecular sciences · 2024
    Article

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Lu Fan *Shenzhen Key Laboratory of Marine Archaea Geo-Omics, Department of Ocean Science and Engineering, Southern University of Science and Technology (SUSTech), Shenzhen, China. fanl@sustech.edu.cn.ORCID http://orcid.org/0000-0002-4184-7211
Dingfeng Wu *Department of Bioinformatics, Putuo People's Hospital, Tongji University, Shanghai, China.
Vadim Goremykin *Research and Innovation Centre, Fondazione Edmund Mach, San Michele all'Adige, Italy.
Jing XiaoDepartment of Bioinformatics, Putuo People's Hospital, Tongji University, Shanghai, China.
Yanbing XuDepartment of Bioinformatics, Putuo People's Hospital, Tongji University, Shanghai, China.
Sriram GargInstitute of Molecular Evolution, Heinrich Heine University, Düsseldorf, Germany.ORCID http://orcid.org/0000-0003-4160-5228
Chuanlun ZhangShenzhen Key Laboratory of Marine Archaea Geo-Omics, Department of Ocean Science and Engineering, Southern University of Science and Technology (SUSTech), Shenzhen, China.
William F MartinInstitute of Molecular Evolution, Heinrich Heine University, Düsseldorf, Germany. bill@hhu.de.ORCID http://orcid.org/0000-0003-1478-6449
Ruixin ZhuDepartment of Bioinformatics, Putuo People's Hospital, Tongji University, Shanghai, China. rxzhu@tongji.edu.cn.ORCID http://orcid.org/0000-0002-5070-6453

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Though it is well accepted that mitochondria originated from an alphaproteobacteria-like ancestor, the phylogenetic relationship of the mitochondrial endosymbiont to extant Alphaproteobacteria is yet unresolved. The focus of much debate is whether the affinity between mitochondria and fast-evolving alphaproteobacterial lineages reflects true homology or artefacts. Approaches such as site exclusion have been claimed to mitigate compositional heterogeneity between taxa, but this comes at the cost of information loss, and the reliability of such methods is so far unproven. Here we demonstrate that site-exclusion methods produce erratic phylogenetic estimates of mitochondrial origin. Thus, previous phylogenetic hypotheses on the origin of mitochondria based on pretreated datasets should be re-evaluated. We applied alternative strategies to reduce phylogenetic noise by systematic taxon sampling while keeping site substitution information intact. Cross-validation based on a series of trees placed mitochondria robustly within Alphaproteobacteria, sharing an ancient common ancestor with Rickettsiales and currently unclassified marine lineages.

Indexed as

AlphaproteobacteriaMitochondriaPhylogenyReproducibility of Results

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.